School of Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.
Acta Trop. 2011 May;118(2):71-9. doi: 10.1016/j.actatropica.2011.03.005. Epub 2011 Mar 31.
Artemisinin combination therapies have decreased malaria associated morbidity and mortality in several parts of the world. On the other hand, malaria cases have increased in sub-Saharan Africa largely due to falciparum resistance to the most frequently used drugs (chloroquine and sulphadoxine/pyrimethamine (SP) combination). Therapeutic failure has also been attributed in part to adverse effects of anti-malarial drugs and patients' non-compliance due to inconvenient dosing schedules. We consider that formulation and evaluation of novel drug delivery systems is not only less expensive than developing new drugs, but may also improve delivery of anti-malarials at the desired rates. In this review we evaluate the therapeutic efficacy of existing anti-malarial drugs and assess the feasibility of developing novel formulations and delivery systems.
青蒿素联合疗法已在世界多个地区降低了疟疾相关的发病率和死亡率。另一方面，由于恶性疟原虫对最常使用的药物（氯喹和磺胺多辛/乙胺嘧啶（SP）组合）产生了耐药性，撒哈拉以南非洲的疟疾病例有所增加。治疗失败也部分归因于抗疟药物的不良反应以及由于剂量方案不便导致的患者不遵医嘱。我们认为，新型药物输送系统的制剂和评估不仅比开发新药便宜，而且还可以提高所需速率的抗疟药物的输送。在本综述中，我们评估了现有抗疟药物的治疗效果，并评估了开发新型制剂和输送系统的可行性。
